Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infections
Up to 1.8% of all hospitalisations are due to acute bacterial skin and skin-structure infections (ABSSSIs) [1]. Often these serious skin infections require intravenous (i.v.) antimicrobials, hospitalisation and/or surgical intervention [2,3]. The majority of ABSSSIs are caused by Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), methicillin-susceptible S. aureus and β-haemolytic streptococci [3,4]. Although many antimicrobials are available to treat ABSSSIs, only a few are available for ABSSSI caused by multidrug-resistant bacteria, and some of these are limited by safety, tolerability and dosing issues [5], the need for monitoring plasma concentrations and/or inconvenient dosage regimens [6].
Source: International Journal of Antimicrobial Agents - Category: Drugs & Pharmacology Authors: David B. Huang, G. Ralph Corey, Thomas L. Holland, Thomas Lodise, William O'Riordan, Mark H. Wilcox, Thomas M. File, Matthew Dryden, Barbara Balser, Eve Desplats, Antoni Torres Source Type: research
More News: Drugs & Pharmacology | Infectious Diseases | MRSA | Multidrug Resistance | Skin | Staphylococcus Aureus | Study | Superbugs